Overview

Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

Status:
RECRUITING

Trial end date:
2028-08-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of Tauroursodeoxycholic Acid (TUDCA) plus Camrelizumab and Regorafenib for patients with advanced hepatocellular carcinoma (HCC) who have progressed on prior systemic treatment with Anti-PD1/PD-L1 plus bevacizumab combination.

Phase:

PHASE2

Details

Lead Sponsor:

Fudan University

Treatments:

camrelizumab
regorafenib
ursodoxicoltaurine